Ingrid Karlsson (Former)
1 – 10 of 15
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.
- Contribution to journal › Scientific review
-
Mark
19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.
- Contribution to journal › Scientific review
- 2019
-
Mark
Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals
- Contribution to journal › Article
- 2016
-
Mark
Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark
- Contribution to journal › Article
- 2010
-
Mark
Enhanced CD4+cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection
- Contribution to journal › Article
-
Mark
Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children.
- Contribution to journal › Article
-
Mark
Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
- Contribution to journal › Article
- 2008
-
Mark
Sensitivity of HIV-1 primary isolates to human anti-CD40 antibody-mediated suppression is related to co-receptor use
- Contribution to journal › Article
- 2007
-
Mark
Biological and genetic evolution of HIV type 1 in two siblings with different patterns of disease progression
- Contribution to journal › Article
-
Mark
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
- Contribution to journal › Article
